Maurie Markman, MD

Articles

5 Abstracts Among SGO Highlights

September 30th 2011

This report highlights 5 abstracts relevant to the current and future management of patients with female pelvic malignancies.

Novel PET Strategy May Predict Utility of Clinical Options

September 29th 2011

The desire to reduce the risk and severity of treatment-related toxicity by rapidly discontinuing ineffective therapy, and the increasing use of highly sensitive imaging technology.

New Clinical Trial Designs Needed for Marker-Based Studies

August 9th 2011

The oncology community is quite conversant with the clinical utility of prognostic tumor markers.

Looking Before Leaping: When to Change Practice Based on ASCO Results

July 19th 2011

Which studies should influence how I manage my patients and what criteria should I use to make these decisions?

Game-Changers: 11 Key Abstracts in ASCO Lineup

July 18th 2011

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

The Internet Dilemma: Awash in Information, Drowning in Ignorance

June 29th 2011

Despite the importance of the recently enacted federal healthcare law, a remarkable 50% of the public does not know its current status.

Right Public Health Message Serves Up Facts Without Panic

June 13th 2011

Despite misgivings among physicians, the Internet is growing as a source of health information for patients.

Concerns Shadow Bright Prospects for Use of EMRs

May 19th 2011

Healthcare professionals in many specialties, particularly oncology, have long wrestled with the complexities and costs of integrating electronic medical records

Dr. Markman on HPV Testing to Detect Cervical Cancer

May 18th 2011

Dr. Markman on HPV Testing to Detect Cervical Cancer

Dr. Markman Discusses the Swedish PSA Screening

May 18th 2011

Dr. Markman Discusses the Swedish PSA Screening

Dr. Markman Discusses the Olaparib Phase II Trial

May 18th 2011

Dr. Markman Discusses the Olaparib Phase II Trial

Dr. Markman Discusses the Importance of Screening

May 18th 2011

Dr. Markman Discusses the Importance of Cancer Screening

Dr. Markman on Potential Neuropathy Biomarkers

May 18th 2011

Dr. Markman on Taxane-Induced Neuropathy Biomarkers

Medical Professionals and Social Networking: The Opportunities, Challenges, and Risks

April 11th 2011

The brave, (relatively) new world of social networking has presented even the medical community with challenges, but with a few precautions fellows can avoid some of the pitfalls associated with an online presence.

Oncology Community Must Guide Public on Gene Testing Nuances

March 8th 2011

The genuine revolution in our understanding of the genetic basis of malignant disease has led to a corresponding interest in defining the risk of developing a particular disease for both individuals and specific populations.

From the Editor: Electronic Alerts Would Help Oncologists Manage Therapy

March 7th 2011

It was not so long ago that designing an optimal treatment plan for an individual cancer patient required only a confirmed histologic/morphologic diagnosis of a particular tumor type and appropriate staging, which was surgically based in most solid tumors.

From the Editor: Internet Analysis Raises Questions in Rare Cancer Care

March 6th 2011

The Internet has been employed in a variety of interesting ways to foster clinical or research agendas.

E-books: Will they impact education and dissemination of medical information?

April 30th 2010

Electronic communication technologies have radically changed our world, transforming almost every aspect of our daily lives. Most of the tasks we need to perform can be handled electronically, from paying bills and shopping to communicating with friends and family.

Web-based Risk Information and the Use of Alternative Medicine for Active Anti-neoplastic Therapy

April 14th 2009

The websites and other resources your patients find on the Internet may downplay or ignore clinical evidence that herbal supplements may promote tumor growth or impair the effectiveness of established cancer treatments.